Table 1.
Hb-HDACIs in clinical trials for cancer treatment. The hydroxamic acid group, which characterizes this class of HDACIs, is represented in the red dotted square.
| Hb-HDACIs | Structure | Chemical name | Formula | Molecular mass |
|---|---|---|---|---|
| Vorinostat |  |
N-hydroxy-N'-phenyl-octanediamide | C14H20N2O3 | 264.32 g/mol |
| Belinostat (PXD101) |  |
(2E)-N-Hydroxy-3-[3-(phenylsulfamoyl) phenyl]prop-2-enamide | C15H14N2O4S | 318.35 g/mol |
| Panobinostat (LBH589) |  |
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3l)ethyl]amino}methyl) phenyl]acrylamide | C21H23N3O2 | 349.42 g/mol |
| Pracinostat (SB939) |  |
(E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide | C20H30N4O2 | 358.48 g/mol |
| Abexinostat (PCI-24781 /CRA-024781) |
 |
3-[(Dimethylamino) methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide | C21H23N3O5 | 397.42 g/mol |
| JNJ-26481585 |  |
N-hydroxy-2-(4-(((1-methyl-1H-indol-3-yl)methylamino) methyl)piperidin-1-yl) pyrimidine-5-carboxamide |
C21H26N6O2 | 394.47 g/mol |
| Dacinostat (LAQ824) |  |
(E)-3-(4-(((2-(1H-indol-3-yl) ethyl)(2-hydroxyethyl)amino) methyl)phenyl)-N-hydroxyacrylamide |
C22H25N3O3 | 379.45 g/mol |
| Resminostat (RAS2410/4SC-201) |  |
(E)-3-(1-((4-((dimethyl amino) methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide |
C16H19N3O4S | 349.10 g/mol |
| CHR-3996 |  |
2-(6-(((6-fluoroquinolin-2-yl) methyl)amino) bicycle [3,1,0]hexan-3-yl)-N-hydroxypy rimidine-5-carboxamide |
C21H20FN5O2 | 393.16 g/mol |